TGFB1I1 Antibody

What is TGFB1I1 and what cellular functions does it regulate?

TGFB1I1 (Transforming Growth Factor beta 1 Induced Transcript 1) is a cofactor of cellular TGF-β1 that interacts with various nuclear receptors. This protein serves as a critical mediator in several cellular processes:

• Functions as a cofactor for TGF-β1 signaling pathway

• Promotes focal adhesion formation

• Contributes to epithelial-mesenchymal transition (EMT) by regulating actin cytoskeleton and vimentin

• Regulates cell proliferation and viability

• Facilitates cell migration

• Links various intracellular signaling modules to plasma membrane receptors

• Regulates both Wnt and TGF-β signaling pathways

Recent studies have demonstrated that TGFB1I1 overexpression correlates with advanced tumor stages in urothelial carcinoma, both in the upper urinary tract and bladder, indicating its potential role in cancer progression . Additionally, research has identified TGFB1I1 as a potential biomarker for chemotherapy sensitivity in colorectal cancer patients .

What are the primary applications for TGFB1I1 antibodies in experimental research?

TGFB1I1 antibodies serve as essential tools in multiple experimental applications:

These applications have proven valuable in studying TGFB1I1's role in cancer progression, EMT, and as a potential prognostic marker. For instance, immunohistochemical analysis has revealed that TGFB1I1 protein localizes to both the nucleus and cytoplasm of cancer cells, providing important insights into its functional distribution .

How does antibody selection differ between polyclonal and monoclonal TGFB1I1 antibodies?

The choice between polyclonal and monoclonal TGFB1I1 antibodies significantly impacts experimental outcomes:

Polyclonal TGFB1I1 Antibodies:

• Recognize multiple epitopes across the TGFB1I1 protein

• Generally provide higher sensitivity due to multiple binding sites

• Better for detecting proteins with low expression levels

• More tolerant of minor protein denaturation or modifications

• Available from various hosts, with rabbit being most common

Monoclonal TGFB1I1 Antibodies:

• Recognize a single epitope on the TGFB1I1 protein

• Provide higher specificity and reduced background

• Ensure greater consistency between experimental batches

• Better for distinguishing between closely related proteins

• Often available as mouse monoclonal antibodies (e.g., clone 4B2-D8)

Selection recommendations based on experimental goals:

• For detecting low abundance TGFB1I1 expression or initial screening, use polyclonal antibodies

• For long-term studies requiring consistent antibody performance or distinguishing between isoforms, select monoclonal antibodies

• For critical experiments, validate findings using both antibody types

Most commercially available TGFB1I1 antibodies target specific regions (N-terminal, middle region, or C-terminal domains), which should be selected based on the experimental question .

What cross-reactivity considerations are important when working with TGFB1I1 antibodies?

TGFB1I1 antibodies demonstrate varying cross-reactivity profiles across species, which must be considered when planning experiments:

Most commercial TGFB1I1 antibodies show reactivity with:

• Human TGFB1I1 (100% predicted reactivity)

• Mouse TGFB1I1 (100% predicted reactivity)

• Rat TGFB1I1 (100% predicted reactivity)

• Dog TGFB1I1 (93% predicted reactivity)

• Cow TGFB1I1 (100% predicted reactivity)

• Rabbit TGFB1I1 (100% predicted reactivity)

• Horse TGFB1I1 (100% predicted reactivity)

• Goat TGFB1I1 (86% predicted reactivity)

• Guinea Pig TGFB1I1 (100% predicted reactivity)

The broad cross-reactivity observed is largely due to the highly conserved nature of certain TGFB1I1 regions across species. For antibodies targeting the middle region (e.g., ABIN2777947), the immunogenic peptide sequence "PEPTGKGSLD TMLGLLQSDL SRRGVPTQAK GLCGSCNKPI AGQVVTALGR" shows high conservation, explaining the wide reactivity profile .

Despite predicted reactivity values, researchers should validate each antibody in their specific experimental system, as actual reactivity may vary from predictions due to differences in epitope accessibility or post-translational modifications.

What validation steps should be performed before using TGFB1I1 antibodies in experimental studies?

Before employing TGFB1I1 antibodies in critical experiments, comprehensive validation is essential:

• Western Blot Validation:

  • Confirm detection of a band at the expected molecular weight (~55 kDa)

  • Test in multiple cell lines with varying TGFB1I1 expression levels

  • Include positive controls (e.g., recombinant TGFB1I1 protein)

• Specificity Assessment:

  • Perform peptide competition assays using the immunizing peptide

  • Test in TGFB1I1 knockdown/knockout models

  • Compare reactivity across multiple antibodies targeting different epitopes

• Application-Specific Validation:

  • For IHC: Optimize fixation, antigen retrieval, and staining conditions

  • For IP: Verify pull-down efficiency with Western blot detection

  • For IF: Confirm expected subcellular localization patterns

• Cross-Reactivity Testing:

  • Validate species reactivity if working with non-human models

  • Test cross-reactivity with closely related proteins

• Batch Testing:

  • Compare new antibody lots with previously validated batches

  • Maintain consistent validation protocols across experiments

How can researchers optimize TGFB1I1 antibody use for detecting EMT markers in cancer tissues?

Optimizing TGFB1I1 antibody protocols for epithelial-mesenchymal transition (EMT) marker detection requires:

• Multiplex Staining Strategy Development:

  • Co-stain tissues with TGFB1I1 antibodies alongside established EMT markers (E-cadherin, vimentin, N-cadherin)

  • Employ spectrally distinct fluorophores for fluorescent detection or sequential chromogenic staining

  • Design antibody panels that minimize cross-reactivity by selecting primary antibodies from different host species

• Tissue Preparation Optimization:

  • Compare fixation methods (formalin, paraformaldehyde, alcohol-based) for optimal epitope preservation

  • Test multiple antigen retrieval conditions (citrate pH 6.0, EDTA pH 9.0) to maximize signal while maintaining tissue integrity

  • Evaluate both heat-induced and enzymatic retrieval methods

• Signal Detection Enhancement:

  • Implement tyramide signal amplification (TSA) for low-abundance targets

  • Utilize high-sensitivity detection systems (polymer-based vs. avidin-biotin)

  • Optimize primary antibody concentration and incubation conditions for each target

• Quantification Method Standardization:

  • Establish digital image analysis protocols for objective quantification

  • Implement colocalization analysis to assess TGFB1I1 association with EMT markers

  • Develop scoring systems that account for staining intensity, percentage, and pattern

Research has demonstrated that TGFB1I1 knockdown decreases EMT markers in urothelial carcinoma cell lines, suggesting direct regulatory relationships . When optimizing staining protocols, consider that TGFB1I1 displays both nuclear and cytoplasmic localization in cancer cells, requiring detection systems capable of visualizing both compartments .

What methodological approaches can resolve discrepancies between Western blot and IHC results when using TGFB1I1 antibodies?

Resolving discrepancies between Western blotting and immunohistochemistry requires systematic troubleshooting:

• Understand Fundamental Technical Differences:

  Parameter	Western Blotting	Immunohistochemistry	Reconciliation Approach
  Protein State	Denatured	Native/partially denatured	Use antibodies validated for both conditions
  Epitope Access	Complete exposure	May be masked in tissue	Optimize antigen retrieval; test multiple epitope targets
  Detection System	Direct band visualization	Signal amplification cascades	Calibrate detection sensitivity across methods
  Sample Preparation	Homogenized lysate	Intact tissue architecture	Consider cellular heterogeneity in tissues

• Antibody-Specific Optimization:

  • Test multiple antibody concentrations specific to each application

  • Evaluate antibodies targeting different TGFB1I1 epitopes

  • Consider using antibodies specifically validated for both applications

• Protocol Refinement Strategy:

  • For IHC: Systematically test multiple antigen retrieval methods and detection systems

  • For Western blotting: Optimize protein extraction, loading amount, and transfer conditions

  • Document all optimization steps and establish standardized protocols

• Control Implementation:

  • Use cell lines with known TGFB1I1 expression levels as controls

  • Include TGFB1I1 knockdown/overexpression controls

  • Process control samples alongside experimental samples

• Complementary Approach:

  • Consider these techniques as complementary rather than contradictory

  • Western blotting provides quantitative expression information

  • IHC reveals spatial distribution and cell-type specific expression

When investigating TGFB1I1 in cancer tissues, remember that subcellular localization may vary between cancer types and cellular contexts, potentially explaining some discrepancies between detection methods .

How should researchers design experiments to investigate TGFB1I1's role in cancer progression?

Designing rigorous experiments to elucidate TGFB1I1's role in cancer progression requires:

• Model System Selection and Validation:

  • Cell Line Models: Select panels representing cancer progression stages

    • For urothelial carcinoma: Include lines from both upper tract and bladder origins

    • For colorectal cancer: Include lines with varying chemotherapy sensitivity profiles

  • Animal Models: Consider both xenograft and genetically engineered models

  • Patient-Derived Models: Incorporate patient-derived organoids where possible

• TGFB1I1 Expression Modulation:

  • Knockdown Approaches: Use siRNA or shRNA for transient/stable suppression

  • CRISPR-Cas9 Knockout: Generate complete TGFB1I1 knockout models

  • Overexpression Systems: Employ inducible or constitutive expression systems

  • Domain-Specific Manipulation: Create truncation or point mutants to identify functional domains

• Functional Assay Selection:

  Cellular Process	Recommended Assays	TGFB1I1 Relevance
  Proliferation	MTT/XTT, BrdU incorporation, colony formation	TGFB1I1 regulates cancer cell proliferation
  Migration	Wound healing, transwell migration	TGFB1I1 facilitates cancer cell migration
  EMT	E-cadherin/vimentin expression, cell morphology	TGFB1I1 promotes EMT in cancer cells
  Signaling	Phospho-protein analysis, reporter assays	TGFB1I1 mediates TGF-β signaling

• Molecular Mechanistic Investigations:

  • Interactome Analysis: Identify TGFB1I1 binding partners using IP-MS

  • Transcriptional Profiling: RNA-seq after TGFB1I1 manipulation

  • Chromatin Interaction: ChIP-seq to identify TGFB1I1-associated genomic regions

  • Post-translational Modifications: Phosphorylation, ubiquitination analysis

• Clinical Correlation Approaches:

  • Tissue Microarray Analysis: High-throughput assessment of TGFB1I1 expression

  • Survival Analysis: Correlate TGFB1I1 expression with patient outcomes

  • Multivariate Analysis: Determine TGFB1I1's independent prognostic value

Research has demonstrated that TGFB1I1 overexpression correlates with advanced tumor stage in urothelial carcinoma and may serve as a biomarker for chemotherapy sensitivity in colorectal cancer , providing foundations for further mechanistic investigations.

What techniques are optimal for investigating TGFB1I1's role in the TGF-β signaling pathway?

Investigating TGFB1I1's function within the TGF-β signaling pathway requires specialized techniques:

• Protein Interaction Analysis:

  • Co-immunoprecipitation (Co-IP): Use TGFB1I1 antibodies to identify binding partners within the TGF-β pathway

  • Proximity Ligation Assay (PLA): Detect in situ protein-protein interactions between TGFB1I1 and TGF-β pathway components

  • FRET/BRET Analysis: Measure real-time interactions between TGFB1I1 and signaling proteins

  • Yeast Two-Hybrid Screening: Identify novel TGFB1I1 interactors in an unbiased manner

• Signaling Dynamics Assessment:

  • Phosphorylation Analysis: Monitor SMAD2/3 phosphorylation after TGFB1I1 manipulation

  • Nuclear Translocation: Track SMAD complex nuclear accumulation in relation to TGFB1I1

  • Reporter Assays: Measure TGF-β transcriptional responses using SMAD-binding element reporters

  • Time-Course Experiments: Analyze signaling kinetics after TGF-β stimulation with/without TGFB1I1

• Transcriptional Regulation Investigation:

  • ChIP-seq: Map TGFB1I1 genomic binding sites and compare with SMAD binding regions

  • RNA-seq: Profile transcriptome changes after TGFB1I1 manipulation ± TGF-β treatment

  • ATAC-seq: Assess chromatin accessibility changes mediated by TGFB1I1 in TGF-β signaling

  • CUT&RUN: High-resolution mapping of TGFB1I1 chromatin interactions

• Functional Pathway Analysis:

  • Domain Mapping Experiments: Identify TGFB1I1 regions required for TGF-β signaling

  • Pathway Inhibitor Studies: Use TGF-β receptor inhibitors with TGFB1I1 manipulation

  • Rescue Experiments: Restore TGFB1I1 in knockout cells to assess signaling recovery

  • 3D Culture Models: Evaluate TGFB1I1's impact on TGF-β-induced morphological changes

• In Vivo Pathway Assessment:

  • Conditional Knockout Models: Tissue-specific TGFB1I1 ablation to assess TGF-β responses

  • TGF-β Response Element Reporters: In vivo pathway activity visualization

  • Tissue-Specific Signaling Analysis: Immunohistochemical assessment of pathway activation

Research has established TGFB1I1 as a cofactor of cellular TGF-β1 that interacts with various nuclear receptors and regulates the TGF-β signaling pathway . These techniques will help elucidate the molecular mechanisms underlying TGFB1I1's signaling functions.

How can multiplexed immunofluorescence protocols be optimized for TGFB1I1 co-detection with other cancer biomarkers?

Developing robust multiplexed immunofluorescence protocols for TGFB1I1 co-detection requires:

• Antibody Panel Design:

  • Select primary antibodies from different host species (e.g., rabbit anti-TGFB1I1 with mouse anti-EMT markers)

  • Verify epitope compatibility with common antigen retrieval methods

  • Test each antibody individually before combining into multiplex panels

  • Include isotype controls for each primary antibody species

• Sequential Staining Strategy:

  • Implement tyramide signal amplification (TSA) for sequential detection

  • Establish complete antibody stripping between rounds

  • Use spectral unmixing to resolve overlapping fluorophore emissions

  • Design panel with brightest fluorophores for lowest abundance targets

• Sample Preparation Optimization:

  • Compare multiple fixatives for optimal multi-epitope preservation

  • Test comprehensive antigen retrieval protocols (heat, enzymatic, pH variations)

  • Evaluate background reduction strategies (autofluorescence quenching, blocking optimization)

  • Assess section thickness effects on signal penetration

• Protocol Validation:

  Validation Parameter	Methodology	Quality Threshold
  Signal-to-Noise Ratio	Quantitative image analysis	>5:1 for each marker
  Cross-Reactivity	Single primary antibody controls	<5% non-specific signal
  Reproducibility	Technical replicates	CV <15% between staining runs
  Specificity	Peptide competition, knockdown controls	>90% signal reduction

• Image Acquisition and Analysis:

  • Standardize exposure settings across experimental cohorts

  • Implement spectral unmixing for fluorophore separation

  • Develop automated segmentation algorithms for cell/tissue compartments

  • Perform quantitative colocalization analysis for TGFB1I1 with other markers

• Recommended Marker Combinations:

  • TGFB1I1 + EMT markers (E-cadherin, vimentin, N-cadherin)

  • TGFB1I1 + TGF-β pathway components (TGF-β receptors, phospho-SMADs)

  • TGFB1I1 + proliferation/apoptosis markers (Ki67, cleaved caspase-3)

Research has demonstrated that TGFB1I1 regulates EMT markers and affects cell migration in cancer models, making multiplexed detection particularly valuable for understanding its role in cancer progression and metastasis .